Restenosis after Coronary Stent Implantation: Cellular Mechanisms and Potential of Endothelial Progenitor Cells (A Short Guide for the Interventional Cardiologist)

Tommaso Gori

German Center for Cardiac and Vascular Research (DZHK) Standort Rhein-Main, Department of Cardiology, University Medical Center Mainz, 55131 Mainz, Germany; tommaso.gori@unimedizin-mainz.de; Tel.: +49-6131-172829

Abstract: Coronary stents are among the most common therapies worldwide. Despite significant improvements in the biocompatibility of these devices throughout the last decades, they are prone, in as many as 10–20% of cases, to short- or long-term failure. In-stent restenosis is a multifactorial process with a complex and incompletely understood pathophysiology in which inflammatory reactions are of central importance. This review provides a short overview for the clinician on the cellular types responsible for restenosis with a focus on the role of endothelial progenitor cells. The mechanisms of restenosis are described, along with the cell-based attempts made to prevent it. While the focus of this review is principally clinical, experimental evidence provides some insight into the potential implications for prevention and therapy of coronary stent restenosis.

Keywords: coronary arteries; inflammation; stent; stent thrombosis; stent restenosis

1. Introduction—Endothelial Progenitor Cells and Stent Failure

Implantation of coronary artery stents is the most commonly used strategy for the treatment of coronary artery disease [1]. Even though their application leads to improved quality of life and survival for millions of patients each year, these therapies are also associated with failures that limit their long-term efficacy. After percutaneous interventions (PCI), the most common cause of long-term failure is in-stent restenosis (ISR). ISR occurs with a frequency that was reported to be as high as 25% to 50% in bare metal stents (now discouraged in the current guidelines); although its rate has become significantly lower with the introduction of drug eluting stents (DES) [2]. DES failure remains a problem that affects, depending on a number of factors, up to 20% of the devices implanted [1]. Beyond the implications for the treatment of these events (the majority of patients requiring further myocardial revascularization procedures), percutaneous treatment of ISR is also associated with a much higher rate of re-failure than treatment of native vessels. Procedural issues such as malaposition or incomplete stent expansion disrupt laminar flow and induced neointima proliferation [3]. In addition, the mechanical trauma caused by the stent implantation, hypersensitivity foreign-body reactions, the thrombogenicity of the stent surfaces which leads to adhesion of platelets and release of chemotactic and inflammatory substances, and, over more prolonged follow-up, progression of atherosclerosis in the stent neointima are all accepted mechanisms that concur with ISR [4–6]. Progenitor cells (PCs) are a heterogeneous group of blood cells that are believed to be involved in repair processes [7–9]. Their role in restenosis and as potential instruments in improving the outcomes of PCI remains unexploited, but interesting attempts have been made. This review will summarize the cellular mechanisms involved in the pathophysiology of stent failure and the potential of PCs to prevent it.
2. Cells Involved in the Pathophysiology of In-Stent Restenosis

Bare metal stent restenosis has affected as many as 50% of the devices implanted. Progressive growth of a fibrotic extracellular matrix resulting in a slowly progressing negative remodeling of the lumen was the typical feature of this complication [2]. In the DES era, the biochemical and cellular mechanisms involved in ISR appear to depend on hypersensitivity and foreign-body reactions, inhibition of healing mechanisms, as well as on proliferative responses triggered by the vascular damage during stent implantation [10,11]. Vascular smooth muscle cell (SMC) proliferation and migration, the synthesis of an extracellular matrix, and the migration of bone-marrow PCs appear to drive its pathophysiology [10,11]. A combination of both local and systemic responses to vessel damage determines whether vascular healing will result in the formation of a protective, smooth and thin, neointima or a restenosis.

Locally, the vascular injury caused by stenting triggers a complex cascade of events that include endothelial denudation, exposure of prothrombotic intima and subsequent inflammation, release of growth factors and cytokines, platelet activation, and SMC proliferation and migration. The result of these processes may be healing or pathological processes such as excessive neointimal hyperplasia (timeframe 6–12 months typically) or neotherogenesis (timeframe > 12 months after PCI), which ultimately cause restenosis. The endothelial activation that follows injury causes degranulation and aggregation of platelets, which are probably the first cellular type involved in the reactions to stents [12,13]. These mechanisms have been summarized recently in a review by Neubauer and Zieger [14]; in short, endothelial injury leads to an increased local bioavailability of ATP, ADP and AMP and a decreased activity of ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1/CD39), a membrane-bound enzyme that converts ATP and ADP into adenosine. Soluble ADP triggers the recruitment and aggregation of platelets during the formation of a hemostatic plug. In addition, Antithrombin III (which normally binds to heparan sulfates of proteoglycans in the endothelial glycocalyx) and thrombomodulin, a membrane-bound thrombin receptor and inhibitor of the thrombin pathway are depleted following endothelial injury, removing two potent inhibitors of platelet activation. All these processes are important pharmacological targets.

In an observational study of 161 patients with recurrent angina after coronary stenting, platelet distribution width, an easily accessible marker of platelet activation, was an independent predictor of stent restenosis (Odd’s ratio 1.2 [1.02–1.4], }p{eq}= 0.025) [15]. Following arterial injury, platelets rapidly adhere and release thromboxane A2; the glycoprotein (GP) IIb/IIIa complex binds to fibrinogen, leading to platelet aggregation and activation [16]. In addition, activated platelets release multiple factors including platelet-derived growth factor (PDGF), which exerts a mitogen and chemotactic effect on SMCs and contributes to oxidative stress, one of the major determinants of the switch of vascular SMCs from a contractile to a synthetic phenotype [17]. Changes in multiple parameters reflective of oxidative stress including malondialdehyde, superoxide dismutase and paraoxonase-1 in patients with ISR confirm the importance of this process [18]. In a randomized trial from our group, potent platelet inhibition with prasugrel (as compared to ticagrelor or clopidogrel) was associated with reduced markers of oxidative stress and it prevented stent-induced systemic endothelial and microvascular dysfunction [19] (which in turn are associated with long-term in-stent restenosis [20]). Histamine released from platelets and mast cells may also cause intimal hyperplasia, as the levels of this mediator were shown to increase by 20 to 90 times in a porcine model of endothelial injury, while in vitro histamine potentiated the PDGF-stimulated proliferation of cultured SMCs [21]. Platelet-derived interleukin-1 increases production of proinflammatory interleukin-6 and interleukin-8, respectively, stimulating SMC migration by actin polymerization and tyrosine phosphorylation of focal adhesion-associated cytoskeletal protein and the proliferation of SMCs [22]. In this context, thrombin also has potent mitogen effects, and the immunosuppressive effect of the drug eluted might slow tissue repair reaction and fibrin removal. The prolonged activation of the thrombotic cascade concurs with the activation of inflammatory
cells (monocytes, T cells, neutrophils), secretion of chemoattractant molecules (MCP-1 or monocyte chemoattractant protein-1, Interleukin (IL)-8) by endothelial and SMCs and the production of growth factors (PDGF, platelet-derived growth factor, bFGF or fibroblast growth factor, TGF or transforming growth factor-beta, IGF, insulin-like growth factor, and VEGF, vascular endothelial growth factor [23]). Platelet-derived extracellular vesicles stimulate SMCs to produce interleukin 6 and express αIIbβ3 and P-selectin, which favor their interaction with monocytes [24]. In addition, platelet-derived microvesicles stimulate endothelial (vWF+ and CD34+) PC proliferation by delivering transforming growth factor (TGF)-β1 in a rat model of arterial injury [25]. Finally, the role of plasma small extracellular vesicles containing miRNA-501-5p of endothelial origin has been demonstrated, as these promote SMC synthesis and are increased in patients with restenosis [26,27].

In the vessel wall, inflammatory responses to the foreign body and the antiproliferative effect of the drug eluted by the stent lead to delayed reendothelialization. Exposure of adhesion molecules (P-selectin, intercellular adhesion molecule-1) stimulates the recruitment of monocytes and the subsequent secretion of inflammatory cytokines (interleukins 6 and 8), resulting in the influx of neutrophils, monocytes and macrophages into the subendothelial space [22]. In line with this, elevated levels of monocytes (odds ratio 1.44, 95% CI: 1.23–1.68, \(p < 0.001\)) and eosinophils (odds ratio: 1.22, 95% CI: 1.09–1.36, \(p = 0.001\)) at three months after PCI are predictors of late in-stent restenosis after drug-eluting stent implantation [28]. The mechanisms that follow have been demonstrated in animal models of ISR: The release of cytokines and growth factors trigger the migration and proliferation of SMCs. Indeed, macropages’ matrix metalloproteinase (MMP) 8 protein promotes SMC differentiation and matrix (neointima) production from adventitial stem/progenitor cells by modulating transforming growth factor-β activity and ADAM10/Notch1 signaling [29]. On the endothelial surface, downregulation of thrombomodulin and upregulation of tissue factor, fibrin, proteoglycan and collagen deposition occur. Von Willebrand factor (vWF), collagen and fibrinogen exposed on the endothelial cells surface and in the injured sites attract platelets that degranulate and secrete mediators, express adhesive proteins (fibrinogen, fibronectin) and surface glycoprotein receptors [30,31]. Following endothelial activation by mechanical trauma, reactive oxygen species are also generated, which causes vasoconstriction and activation of a prothrombotic phenotype with further increased synthesis of various cytokines [32]. Finally, in addition, the drugs delivered by the stents, such as paclitaxel and sirolimus, have been shown to induce tissue factor and PAI-1 expression and inhibit tPA and induce apoptosis, and to stimulate oxidative stress, which further delays endothelial restoration and function [33]. Although their role in restenosis remains unclear, mast cells release chymase, which lead to the production of angiotensin II and tumor growth factor-β, resulting in fibroblast proliferation and neointimal formation [34,35]. Inhibitors of chymase expression indeed inhibit neointimal formation in animal models [36].

3. The Role of Progenitor Cells

Importantly, while surely causing proliferation, all these inflammatory mechanisms might also have additional effects mediated by the recruitment of PCs (PCs). The processes mediated by the recruitment of these cells are also complex, and may work both in the direction of favoring reparatory processes but also in promoting restenosis.

The concept that stent implantation might result in the mobilization of PCs and that these cells might be involved in reparative processes but also in hyperplasia was proposed in the late 1990s and early 2000s [37–39]. In their original murine model of carotid injury, Werner et al. demonstrated that administration of rosuvastatin enhanced the colonization of bone marrow-derived endothelial cells expressing von Willebrand factor and cadherin in the injured vessel wall reducing neointimal formation [40]. Similarly, direct intravenous transfusion of spleen-derived endothelial PCs double positive for Dil-Ac-LDL and lectin was associated with homing of the transfused cells to the injury site, and lectin binding confirmed their endothelial phenotype. Reduced neointima formation was also observed in transfused animals [41]. Of note, the recruitment of PCs to sites of injury is also mediated
and supported by platelets; in animal models, platelet-derived mediators such as the stromal cell-derived factor-1 or the platelet-derived factor AB promote the adhesion and differentiation of human CD34+ cells (a rather undifferentiated form of PC which has the potential to differentiate into endothelial cells but also into both a myeloid and a lymphoid lineage) to the endothelium, favoring their homing to sites of injury [42]. In addition, in vitro, platelet aggregates facilitate tethering and rolling of CD34+ cells via P-selectin binding; fibrin-containing thrombi attract CD34+ cells to the site of injury, promoting their differentiation toward a mature endothelial cell phenotype [43].

Importantly, other studies have provided evidence against the role of PCs in arterial repair. In the mouse model of Hagensen et al. and Tsuzuki, homing of circulating cells was not observed and the principal mechanism of repair was migration of flanking endothelial cells [44,45]; in the study by Tanaka, the origin of reparatory cells was dependent on the model of injury used and not the same for all models [46].

Significant controversy also exists regarding the origin of PCs, their role and function once they migrate into the vessel. With regard to the origin, while the bone marrow may produce cells that support angiogenesis in vessel walls, it does not appear to supply cellular populations that mature into endothelial cells [45,47], and it has been proposed that PCs may arise directly from a subadventitial “vasculogenic zone” [48]. As briefly described above, adventitial stem/progenitor cells have been attributed an important role in neointima proliferation following arterial injury [49]; however, their role as a target of therapy or prevention remains unexplored. With regard to the type of cells designated as PCs, the CD (“cluster of differentiation”, also known as “cluster of designation” or “classification determinant”) protocol is used for the identification of the different cell types based on their surface molecules. Applied to the classification of endothelial PCs, endothelial PCs were initially identified as CD34+ cells (as opposed to “shedded” mature endothelial cells, which are CD34− but KDR+, CD31+, VEGFR2+)). These CD34+ early-outgrowth cells, also called “endothelial cells colony forming units” [50], originally identified as a potential mechanism of endothelial colonization and regeneration, are indeed recruited after vascular injury [51,52], but their proliferative potential and capacity to form mature endothelial cells is limited. While these cells still support vascular repair indirectly via phagocytic and paracrine secretory activities, more differentiated PCs, the late-outgrowth endothelial PCs [47], are capable of maturing into functioning endothelium. These cells have a higher proliferative potential and express CD31 and KDR, while disagreement exists regarding whether cells identified by their CD133 [53] may mature into endothelial cells or not.

Beyond endothelialization and neointima production, PCs, therefore, also have regulatory functions as they release paracrine mediators, including the vascular endothelial growth factor or the hepatocyte growth factor that are involved in the vascular repair processes by activating both resident endothelial cells and fibroblasts to produce an extracellular matrix [54]. Although proliferation of SMCs and production of the intercellular matrix are the main drivers of neointima formation and restenosis following percutaneous interventions, other types of PCs have a regulatory effect on these cells. For instance, endogenous c-kit+ stem/PCs (which itself do not differentiate into endothelial or SMCs) evolve into monocytes/macrophages and granulocytes, which modulate vascular immunoinflammatory responses to endothelial injury [55]. Similarly, exposure of SMCs to PC mediators or microparticles causes them to increase their production of an extracellular matrix [56] while direct cell–cell contacts between PCs and SMCs inhibit these changes and actually protect from the induction of a synthetic phenotype by cholesterol loading [56]. Thus, the role of PCs in the pathophysiology of coronary restenosis after PCI is complex, as PCs, in different contexts, may have either beneficial or detrimental effects (Figure 1).
Figure 1. PCI results in arterial injury and exposure of a subendothelial proinflammatory environment (1). Circulating PCs are then attracted to the site of vascular injury and support repair by (2) transdifferentiating into endothelial cells or (3) paracrine production of chemokines (red), which stimulate native endothelial cell proliferation. The same processes may, however, (4) lead to SMCs proliferation and switch to a synthetic phenotype, causing restenosis.

4. Progenitor Cells Counts and Outcome after Stenting

A limited number of studies have investigated the relationship between PC counts and restenosis or cardiovascular outcomes after stenting. Although it is well accepted that PCs are involved in vessel repair and may play a role in post-PCI processes, discordant results regarding the quantitative relationship between PC numbers and extent of restenosis have been reported. Of note, most of these studies were too small to provide definitive evidence. In addition, a number of factors may influence endothelial PC count and, therefore, act as confounder. These include, for instance, age and gender, diabetes, family history, hypertension and hypercholesterolemia, all of which are associated with a quantitative reduction and functional inhibition of PCs (both mature, i.e., CD34+/CD133+/KDR+, and less mature, i.e., CD34+) [55,57–60]. It is believed that a dysfunction of PCs may at least partially explain the association between patient characteristics such as age, diabetes mellitus, hyperlipidemia and renal impairment and the risk of restenosis [61]. On the other side, the administration of nitric oxide donors such as organic nitrates and/or physical exercise may actually increase the counts of CD133+, CD34+ and vascular endothelial growth factor receptor positive cells, as well as their proliferation activity, adhesion and migration ability in patients with coronary artery disease [62]. Finally, the impact of various other pharmacological interventions on the number and function of PCs has also been shown, including statins, angiotensin converting enzyme inhibitors, angiotensin blockers,
beta-blockers and clopidogrel [63,64]. Risk factors also interact with these responses. In diabetic patients, Lee et al. demonstrated no increase in PC levels after elective PCI, an observation which was later confirmed by Fadini et al. [65,66].

With bare-metal stents, post-PCI increases in CD43+, or pre-PCI higher levels of CD133+, and CD14+ PCs have been proposed to identify patients at higher risk of developing restenosis in the reports by Inoue et al. and Pelliccia et al. (n = 40 and n = 155) [67,68]. Interestingly, in the Inoue paper, mononuclear PCs differentiating into both endothelial cells and alpha-smooth muscle actin-positive smooth muscle-like cells were observed. While the former may result in stent healing, the latter may contribute to restenosis. Implantation of sirolimus-eluting stents suppressed both types of differentiation. Notably, the same authors also reported differences in the counts of CD34+/CD133+/CD45null and CD34+/KDR+ cells based on the stent type (with a larger response for a newer-generation ultra-thin strut DES as compared to a second-generation DES) group. Neointimal thickness and neointimal coverage rate were proportionally greater in the former [69]. In the paper by Pelliccia, 30 of the 155 patients showed in-stent restenosis at 8 months. The absolute counts of CD34+/KDR+/CD45− cells (i.e., progenitors of endothelial lineage) and of CD133+/KDR+/CD45− cells (i.e., progenitors of endothelial cells at an earlier stage) were significantly higher in these patients. In the study by Schober et al. (n = 17), CD34 + PC counts increased after PCI in patients who later developed restenosis, while they actually decreased in patients with good outcomes [70]. In the paper by DeMaria et al., patients (n = 20) undergoing elective PCI were randomized to bare metal stent alone or with drug coated balloon; neointimal hyperplasia and percentage were linearly correlated with CD34+ CD45dimKDR+ EPC levels at the time of implantation, while the percentage of uncovered struts was negatively associated, which confirms the dual role for these cells in determining stent endothelialisation but also neointimal growth. Other investigations reported a negative, or nonexistent association of neointimal hyperplasia with CD34+ PC counts [71].

With drug-eluting stents, Sakuma et al. observed an increase in circulating CD34+ CD133+ CD45 low cells and serum levels of biomarkers relevant to stem cell mobilization in patients treated with bare metal stents but not in those treated with DESs. In line with this, the percentage of uncovered struts was higher in the DES group compared with the BMS group, and PC numbers correlated with neointimal area. In vitro, sirolimus, zotarolimus and everolimus dose-dependently inhibited the differentiation of mononuclear cells into endothelial-like cells [72]. In the study by Montenegro et al. no significant association between PC counts (defined as CD45− CD34+ CD31+ CD133/2+ CD309+ cells) and the incidence of restenosis was evident, even though there was a trend towards higher PC counts before and after PCI in patients who would later develop restenosis. In this study, a decrease in PC counts was observed in two-thirds of the patients [73]. The size of the study (n = 37) might, however, limit the capacity of this study to detect differences. Finally, in a meta-analysis including nine studies, lower baseline CD34+ PC counts were associated with a significantly greater occurrence of in-stent restenosis (HR 1.33; 95% CI 0.97–1.82, p = 0.045) [74]. Of note, procedural characteristics (beyond the type of stent implanted) might also act as confounders. In a recent study in patients undergoing DES implantation, Jimenez-Quevedo et al. found that the systemic response (increase in the circulating CD133+/KDR+/CD45 low cells at 1 week after stenting) was proportional to the degree of vessel wall injury as manifested by intravascular imaging criteria (number of dissections, the number of quadrants with dissections; the length of edge dissections; and the number of dissections at the borders); in addition, these parameters of vessel wall injury were shown to be prognostic determinants of in-stent neointimal growth at 9 months [46]. In sum, PCI and arterial injury lead to mobilization of PCs, but the influence of risk factors (which are associated with reduced PC counts but also with increased risk of restenosis) and the type of stents implanted (modern ones being less traumatic and more biocompatible) complicate this relationship.
5. Stents Capturing Endothelial-Progenitor Cells

While the discussion of new stent platforms with more biocompatible (or no) polymer, thinner struts, streamlined design, goes beyond the scope of this paper, cell-based interventions have also been proposed to facilitate stent healing.

With the advent of DESs, the introduction of cytostatic or cytotoxic drugs that produce the above-described long-lasting inflammatory responses might be associated with long-term restenosis. This concept led to the development of bioengineered platforms featuring an antibody able to capture PCs on their luminal surface with the goal that these cells might mature into endothelial cells and favor healing of the stent surface. Upon implantation, the increased rate of capture of circulating PCs would promote endothelialization, reducing the risk of restenosis and thrombosis (and potentially leading to a reduced need for dual antiplatelet therapy). In an effort to improve stent healing, stainless steel stents coated with monoclonal antibodies anti-CD133, CD34 and CD146, i.e., able to bind and retain endothelial PCs, were developed. The first device of this type was the Genous monoclonal anti-human CD34 coated stent. This EPC-capture bare metal stent was covered by a covalently coupled polysaccharide polymer with embedded CD34 antibodies. In vitro studies confirmed that CD34 antibodies stents promoted endothelial coverage. In a porcine model, endothelialization (as assessed by scanning electron microscopy and histology) at 14 and 28 days was increased in the groups which received anti-CD34 antibody coated stents and HC-anti-CD34 antibody coated stents combined with sirolimus-eluting stents as compared to a “first generation” stent eluting sirolimus alone (respectively, 97 ± 3%, 95 ± 4%, 74 ± 8%: p = 0.042). Neointima proliferation at 28 days was also reduced in the group receiving combined therapy or sirolimus alone, but it was larger in those who had received anti-CD34 antibodies without sirolimus (neointima, in µm: 131 ± 44 vs. 185 ± 87 vs. 276 ± 108: p = 0.022) [75]. The first trial conducted with this device, the “Healing-FIM trial”, demonstrated an increased adhesion of CD34+ cells on the surface of the device as compared to standard bare-metal stents, but no difference in the amount of neointima hyperplasia during follow-up [76]. Further developments of PC-capturing stents included a combination of the use with a paclitaxel-coated balloon or with a DES [77]. The Combo stent (OrbusNeich Medical, Fort Lauderdale, FL, USA) features adluminal CD34-EPC capturing technology with abluminal release of sirolimus-eluting to minimize neointima formation. Preclinical trials in porcine models showed inhibition of neointima proliferation as compared to first-generation, thick-strut sirolimus-eluting stents (Cypher, Cordis, New Brunswick, USA) [78]. While clinical studies confirmed the non-inferiority in terms of safety and efficacy as compared to first-generation DESs up to 5 years and in single-arm registries [79,80], later lines of evidence demonstrated (in line with the results of the above porcine model) an increased rate of restenosis as compared to modern DESs with thin struts, biocompatible (or no) polymer, and “modern–limus eluting drug” [81–84]. In the Japan–USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNeich’s Combo StEnt (HARMONEE) study, despite noninferiority of the Combo stent to Xience (Abbott Vascular, Santa Clara, CA, USA), a trend towards more frequent target vessel failure at 12 months in the COMBO group was observed. Similar data were reported by the SORT OUT X trial, a randomized, multicenter, single-blind, trial in which 3146 patients were randomized to the antibody-coated stent or to the sirolimus-eluting Orsiro stent (Biotronik, Bülach, Switzerland) [83]. In addition, in this study, despite noninferiority in terms of death, cardiac death and myocardial infarction at 12 months, the Combo stent led to an increased risk of target lesion revascularization. In the above mentioned meta-analysis, the increase rate of target lesion revascularization following implantation of the COMBO stent was confirmed [74]. Beyond differences in the DES technologies (e.g., different strut thickness, 100 µm for Combo and 60–81 µm for Orsiro or Xience), at least three hypotheses might contribute to explain these findings: the stent scaffold itself; the use of CD34, a surface antigen that is not exclusive to PCs and therefore might result in nonspecific binding of other PCs, with the potential of actually promoting neointima hyperplasia instead of inhibiting it; the fact that PC are reduced and dysfunctional in patients with coronary artery
disease, as suggested by the fact that patients with higher titers of circulating CD34+ KDR+
EPC had lower rates of ISR compared to patients with reduced levels of PCs. This latter
possibility appears to suggest that a combined strategy of stimulating the release of PCs
from the bone marrow (see below) and improving the capture of these cells at the level of
the stent might provide the desired benefit.

With regard to the second issue, stents covered with CD34 antibodies might actually
attract cells incapable of forming a new endothelial layer, paradoxically resulting in
competition and reduced binding of “true” endothelial PCs (CD31+ or VEGFR2+). In
a porcine model, a cobalt chromium stent coated with a CD31-mimetic peptide showed
complete endothelialization already at seven days postimplantation, with no activated
platelets/leukocytes, and neointima development at 28 days was significantly reduced
compared to bare metal stents and showed, unlike DES, no thrombosis [85]. Other animal
studies have addressed the hypothesis that combining CD133 with CD34, or using CD133
instead of CD34 capturing stents, might improve the endothelialization-fostering capacities
of the platform. Using this strategy appears to lead to prolonged time of cell adhesion
and numerically larger PC capture, enhanced endothelialization and reduced in-stent
restenosis rates [86,87], but a CD133 stent was also associated with increased neointima
proliferation in a porcine model [88]. Further studies focused on CD146, which is supposed
to be expressed by late PCs, showed a further improvement in cell capture efficiency as
compared to CD133 stents [89]. This advantage translated into a decreased neointimal
rate and stenosis area, an increased lumen area (all improved by 30–60%) as compared
to a bare metal stent in a porcine model. Whether this will translate in improved patient
outcomes, and the effectiveness of other technologies such as magnetic molecules, aptamers
and specific peptides [58,90] or in vitro endothelialized stents [91], will need to be tested in
the future.

6. Administration of PCs

The dual role of PCs—on one side as reparative cells, on the other as promoters of
proliferation—is confirmed by studies investigating the effect of exogenous PC administra-
tion in settings of vascular injury. Following carotid wire injury in athymic mice, injection
of PCs resulted not only in reduced neointima formation but also in altered cellular com-
position of the neointima with augmented accumulation of SMCs [56]. In a similar rat
model, transplanted PCs promoted reendothelialization and inhibited neointimal hyper-
plasia through production of paracrine cytokines, while differentiation of PCs into mature
endothelial cells was not observed [92]. In vitro, mechanical injury of SMCs was associ-
ated with the release of CXCL12, a key regulator for the mobilization of stem and PCs
into peripheral blood and their subsequent recruitment to sites of tissue damage or stress,
resulting in enhanced recruitment of EPCs to SMCs [93]. The question therefore arises, how
to separate the positive effects of PCs from the negative ones. For instance, in an animal
model of wire-induced endothelial damage, injection of PCs pretreated with netrin-1 (an
axon-guiding protein that stimulates angiogenesis and cardioprotection via induction of
the release of nitric oxide) substantially attenuated neointimal formation. EPC proliferation,
nitric oxide production and resistance to oxidative stress-induced apoptosis were increased
in this model [94]. In rabbits, implantation of a PC-capturing stent expressing anti-CD34
and anti-VEGFR-2 antibodies followed by PC infusion decreased neointima proliferation,
in-stent restenosis and thrombus formation but had no impact on neointimal hyperplasia
inhibition [95].

To date, no study has tested the effect of PC infusion in patients undergoing coronary
stenting. However, a number of studies in patients with myocardial infarction, peripheral
artery disease, pulmonary hypertension and heart failure have been performed with
inconsistent results (Table 1). In the most recently published study, the effect of CD34+ cells
infusions were tested in patients with microvascular angina [96]. Coronary microvascular
angina is typical of patients with evidence of ischemia but without obstructive coronary
artery disease; for these patients no specific therapy exists. In this recent study, 20 patients
with microvascular angina received autologous CD34+ cell therapy, which resulted in an increase in coronary flow reserve from $2.08 \pm 0.32$ at baseline to $2.68 \pm 0.79$ at 6 months after treatment ($p < 0.005$) and a corresponding reduction in angina frequency ($p < 0.004$). In the setting of myocardial infarction, recent meta-analyses summarized the results of multiple trials conducted using different types of PCs. In the work of Wollert et al., including 12 trials, intracoronary cell therapy was associated with no improvement in patient prognosis or changes in left ventricular function [97]. In the meta-analysis of Xu et al., early (within 5 days after myocardial infarction) reinfusion of PCs in patients with reduced ejection fraction was associated with an improvement in contractility [98]. In sum, while PC therapy appears to be safe, its efficacy is at least controversial and its effects in setting of PCI have not yet been tested.

Table 1. Studies of PC therapy early after stenting for AMI.

| Author, Year              | Days from Reperfusion, \( (n \text{ of Patients}) \) | Type of Trial                | Type of PC                                  | Outcome                                      |
|---------------------------|------------------------------------------------------|------------------------------|---------------------------------------------|----------------------------------------------|
| Schächinger 2004 [99]     | 5 (101)                                               | Parallel, randomized         | Autologous bone-marrow mononuclear cells   | Improved LVEF                                |
| Wollert, 2004 [100]       | 5 (39)                                                | Randomized                   | Autologous bone-marrow mononuclear cells; <1% CD34+ | Improved LVEF                                |
| Lunde, 2006 [101]         | 6 (50)                                                | Randomized                   | Autologous bone-marrow mononuclear cells; ~1% CD34+ | No effect                                   |
| Tendera, 2009 [102]       | 7 (80)                                                | Randomized                   | CD34+, CXCR4+ (endothelial)                | No effect                                   |
| Roncalli, 2011 [103]      | 9 (52)                                                | Randomized                   | Autologous bone-marrow mononuclear cells   | SPECT evidence of improved viability         |
| Traverse, 2011 [104]      | 17 (58)                                               | Randomized                   | Autologous bone-marrow mononuclear cells; ~2.5% CD34+, ~1% CD133+ | No effect                                   |
| Makkar, 2012 [105]        | ~62 (17)                                              | Parallel                     | CD105+                                      | MRI evidence of improved viability          |
| Traverse, 2012 [106]      | 3 or 7 (79)                                           | Randomized                   | CD34+ (1% CD34+, CD133+)                   | No effect                                   |
| Wöhrle, 2013 [107]        | 6 (29)                                                | Randomized                   | CD34, CD45, CD133 and vascular endothelial growth factor-R2 | No effect                                   |
| Sürder, 2013 and 2020 [108,109] | 5 (51)                                                | Randomized                   | CD34+, CD133+                              | No effect                                   |
| Peregud-Pogorzelska, 2020 [110] | 1 (15)                                                | Parallel, non-randomized     | Autologous lineage-negative (LIN-) stem/PCs | Earlier decrease in troponin and BNP levels, smaller LV diameter at 12 months. |
| Nicolau, 2018 [111]       | Not reported (83)                                     | Double-blind, randomized, multicenter study | Autologous bone-marrow mononuclear cells | No effect                                   |

BNP: brain natriuretic peptide. LV: left ventricle.

7. Conclusions

Percutaneous coronary interventions cause mechanical injury and vascular inflammation. Additionally, the presence of a foreign body and the proinflammatory effects of the
polymer and the drug eluted by the stent stimulate complex processes involving endothelial cells, SMCs, platelets and inflammatory cells as well as endothelial PCs. These cell types are involved in both repair phenomena but also neointimal proliferation and restenosis. To date, stent platforms covered with anti-(CD43+)-PC have not proven superior (and in several studies have shown inferiority) as compared to modern thin-strut biocompatible DESs. Platforms coated with other antibodies appear to provide more positive results, but clinical data are missing. The potential of other approaches (including PCs of non-endothelial lineage) also remains to be tested. While studies exist in the setting of myocardial infarction and heart failure, currently no data are available on the effect of autologous re-transfusion of (non-endothelial) PCs following PCI. While modern DES appear to be safe and effective, new paradigms of therapies, aimed at exploiting the regenerative potential of endothelial PCs, still find no application.

Funding: T.G. from DZHK. There was no support for this specific work.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Timmis, A.; Townsend, N.; Gale, C.; Grobbée, R.; Maniadakis, N.; Flather, M.; Wilkins, E.; Wright, L.; Vos, R.; Bax, J.; et al. European society of cardiology: Cardiovascular disease statistics 2017. Eur. Heart J. 2018, 39, 508–579. [CrossRef] [PubMed]
2. Moses, J.W.; Leon, M.B.; Popma, J.J.; Fitzgerald, P.; Holmes, D.R.; O’Shaughnessy, C.; Caputo, R.P.; Kereiakes, D.J.; Williams, D.O.; Teirstein, P.; et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 2003, 349, 1315–1323. [CrossRef] [PubMed]
3. Ng, J.C.K.; Lian, S.S.; Zhong, L.; Collet, C.; Foin, N.; Ang, H.Y. Stent malapposition generates stent thrombosis: Insights from a thrombosis model. Int. J. Cardiol. 2022, 353, 43–45. [CrossRef] [PubMed]
4. Joner, M.; Finn, A.V.; Farb, A.; Mont, E.K.; Kolodgie, F.D.; Ladich, E.; Kutys, R.; Skorija, K.; Gold, H.K.; Virmani, R. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 2006, 48, 193–202. [CrossRef]
5. Krüger-Genge, A.; Hiebl, B.; Franke, R.P.; Lendle, A.; Jung, F. Effects of Tacrolimus or Sirolimus on the adhesion of vascular wall cells: Controlled in-vitro comparison study. Clin. Hemorheol. Microcirc. 2017, 67, 309–318. [CrossRef]
6. Braun, S.; Latour, R.A.; Reinthaler, M.; Landmesser, U.; Lendlein, A.; Jung, F. In vitro thrombogenicity testing of biomaterials. Adv. Healthc. Mater. 2019, 8, e1900927. [CrossRef]
7. Chambers, S.E.J.; Pathak, V.; Pedrinì, E.; Soret, L.; Gendron, N.; Guerin, C.L.; Stitt, A.W.; Smadja, D.M.; Medina, R.J. Current concepts on endothelial stem cells definition, location, and markers. Stem Cells Transl. Med. 2021, 10 (Suppl. 2), 554–561. [CrossRef]
8. Fadini, G.P.; Mehta, A.; Dhindsa, D.S.; Bonora, B.M.; Sreejit, G.; Nagareddy, P.; Quyyumi, A.A. Circulating stem cells and cardiovascular outcomes: From basic science to the clinic. Eur. Heart J. 2020, 41, 4271–4282. [CrossRef]
9. Fan, D.; Wu, H.; Pan, K.; Peng, H.; Wu, R. Regenerating damaged myocardium: A review of stem-cell therapies for heart failure. Cells 2021, 10, 3125. [CrossRef]
10. Virmani, R.; Farb, A. Pathology of in-stent restenosis. Curr. Opin. Lipidol. 1999, 10, 499–506. [CrossRef]
11. Yutani, C.; Ishibashi-Ueda, H.; Suzuki, T.; Kojima, A. Histologic evidence of foreign body granulation tissue and de novo lesions in patients with coronary stent restenosis. Cardiology 1999, 92, 171–177. [CrossRef] [PubMed]
12. Becker, R.C.; Sexton, T.; Smyth, S.S. Translational implications of platelets as vascular first responders. Circ. Res. 2018, 122, 506–522. [CrossRef] [PubMed]
13. Hytonen, J.; Leppanen, O.; Braesen, J.H.; Schunck, W.H.; Mueller, D.; Jung, F.; Mrowietz, C.; Jastrow, M.; von Bergwelt-Baildon, M.; Kappert, K.; et al. Activation of peroxisome proliferator-activated receptor-delta as novel therapeutic strategy to prevent in-stent restenosis and stent thrombosis. Arterioscler. Thromb. Vasc. Biol. 2016, 36, 1534–1548. [CrossRef] [PubMed]
14. Neubauer, K.; Zieger, B. Endothelial cells and coagulation. Cell Tissue Res. 2022, 387, 391–398. [CrossRef] [PubMed]
15. Chai, D.; Yang, X.; Wang, A.; Lu, S.; Dai, Y.; Zhou, J. Usefulness of platelet distribution width and fibrinogen in predicting in-stent restenosis with 2 stable angina and type 2 patients with diabetes mellitus. Front. Cardiovasc. Med. 2022, 9, 710804. [CrossRef]
16. Reinthaler, M.; Jung, F.; Landmesser, U.; Lendlein, A. Trend to move from permanent metals to degradable, multifunctional polymer or metallic implants in the example of coronary stents. Expert Rev. Med. Devices 2016, 13, 1001–1003. [CrossRef]
17. Badran, A.; Nasser, S.A.; Mesmar, J.; El-Yazbi, A.F.; Bitto, A.; Fardoun, M.M.; Baydoun, E.; Eid, A.H. Reactive oxygen species: Modulators of phenotypic switch of vascular smooth muscle cells. Int. J. Mol. Sci. 2020, 21, 8764. [CrossRef]
18. Li, X.; Guo, D.; Chen, Y.; Hu, Y.; Zhang, F. Complex coronary instant chronic total occlusion lesions: Oxidative stress, inflammation, and coronary stent lengths. *Oxidative Med. Cell. Longev.* 2021, 2021, 8815048. [CrossRef]

19. Schnorbus, B.; Daiber, A.; Jurk, K.; Warnke, S.; Koenig, J.; Lackner, K.J.; Munzel, T.; Gori, T. Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: A randomized, blinded, parallel study. *Eur. Heart J.* 2020, 41, 3144–3152. [CrossRef]

20. Paltt, G.; Pascre, V.; Melfi, R.; Goffredo, C.; Chello, M.; D’Ambrosio, A.; Montesanti, R.; Di Sciascio, G. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. *Circulation* 2005, 111, 70–75. [CrossRef]

21. Fang, Y.L.; Namiki, H.; Tsunoda, E.; Shioda, S.; Shibata, M.; Nakatani, M.; Katagiri, T.; Takeyama, Y.; Ohata, H.; Honda, K.; et al. Marked increase in the histamine content of neointima after stent implantation of pig coronary artery and growth-promoting effects of histamine in smooth muscle cells. *Life Sci.* 2005, 77, 241–251. [CrossRef] [PubMed]

22. Clare, J.; Ganly, J.; Bursill, C.A.; Sumer, H.; Kingshott, P.; de Haan, J.B. The Mechanisms of restenosis and relevance to next generation stent design. *Biomolecules* 2022, 12, 430. [CrossRef] [PubMed]

23. Gori, T. Vascular wall reactions to coronary stents-clinical implications for stent failure. *Life Sci.* 2021, 11, 63. [CrossRef] [PubMed]

24. Vajen, T.; Benedikter, B.J.; Heinzmann, A.C.A.; Vasina, E.M.; Henskens, Y.; Parsons, M.; Maguire, P.B.; Stassen, F.R.; Heemskerk, J.W.M.; Schurgers, L.J.; et al. Platelet extracellular vesicles induce a pro-inflammatory smooth muscle cell phenotype. *J. Extracell. Vesicles* 2017, 6, 1322454. [CrossRef]

25. Yan, J.; Bao, H.; Fan, Y.J.; Jiang, Z.L.; Qi, Y.X.; Han, Y. Platelet-derived microvesicles promote endothelial progenitor cell proliferation in intimal injury by delivering TGF-beta1. *FEBS J.* 2020, 287, 5196–5217. [CrossRef]

26. Gao, X.F.; Wang, Z.M.; Chen, A.Q.; Wang, E.; Luo, S.; Gu, Y.; Kong, X.Q.; Zuo, G.F.; Jiang, X.M.; Ding, G.W.; et al. Plasma small extracellular vesicle-carried miRNA-501-5p promotes vascular smooth muscle cell phenotypic modulation-mediated in-stent restenosis. *Oxidative Med. Cell. Longev.* 2021, 2021, 6644970. [CrossRef]

27. Gao, X.F.; Wang, Z.M.; Wang, F.; Gu, Y.; Zhang, J.J.; Chen, S.L. Exosomes in coronary artery disease. *Int. J. Biol. Sci.* 2019, 15, 2461–2470. [CrossRef]

28. Li, S.; Qiu, H.; Lin, Z.; Fan, L.; Guo, Y.; Zhang, Y.; Chen, L. The early predictive value of circulating monocytes and eosinophils in coronary DES restenosis. *Front. Cardiovasc. Med.* 2022, 9, 764622. [CrossRef]

29. Yang, F.; Chen, Q.; Yang, M.; Maguire, E.M.; Yu, X.; He, S.; Xiao, R.; Wang, C.S.; An, W.; Wu, W.; et al. Macrophage-derived MMP-8 determines smooth muscle cell differentiation from adventitium stem/progenitor cells and promotes neointima hyperplasia. *Cardiovasc. Res.* 2020, 116, 211–225. [CrossRef]

30. Kruger-Genge, A.; Blocki, A.; Franke, R.P.; Jung, F. Vascular endothelial cell biology: An update. *Int. J. Mol. Sci.* 2019, 20, 4411. [CrossRef]

31. Mojzisch, A.; Brehm, M.A. The manifold cellular functions of von willebrand factor. *Cells* 2021, 10, 2351. [CrossRef] [PubMed]

32. Jain, M.; Chauhan, A.K. Role of integrins in modulating smooth muscle cell plasticity and vascular remodeling: From expression to therapeutic implications. *Cells* 2022, 11, 646. [CrossRef] [PubMed]

33. Miyakawa, A.A.; Girao-Silva, T.; Krieger, J.E.; Edelman, E.R. Rapamycin activates TGF receptor independently of its ligand: Implications for endothelial dysfunction. *Clin. Sci.* 2018, 132, 437–447. [CrossRef] [PubMed]

34. Niccoli, G.; Montone, R.A.; Sabato, V.; Crea, F. Role of allergic inflammatory cells in coronary artery disease. *Circulation* 2018, 138, 1736–1748. [CrossRef]

35. Takai, S.; Miyazaki, A. Effect of chymase inhibitor on vascular proliferation. *Jpn. J. Pharmacol.* 2002, 90, 223–227. [CrossRef]

36. Zhang, C.; Zhang, B.; Wang, H.; Tao, Q.; Ge, S.; Zhai, Z. Tumor necrosis factor alpha-stimulated gene-6 (TSG-6) inhibits the MMP-8 drive in early neointima formation and smooth muscle cell migration. *Arterioscler. Thromb. Vasc. Biol.* 2005, 22, 1567–1572. [CrossRef]

37. Tsai, S.; Butler, J.; Rafii, S.; Liu, B.; Kent, K.C. The role of progenitor cells in the development of intimal hyperplasia. *J. Vasc. Surg.* 2009, 49, 502–510. [CrossRef]

38. Simard, T.; Jung, R.G.; Motazedian, P.; Di Santo, P.; Ramirez, F.D.; Russo, J.J.; Labinaaz, A.; Yousef, A.; Anantharam, B.; Pourjadbab, A.; et al. Progenitor cells for arterial repair: Incremental advancements towards therapeutic reality. *Stem Cells Int.* 2017, 2017, 2070498. [CrossRef]

39. Asahara, T.; Murohara, T.; Sullivan, A.; Silver, M.; van der Zee, R.; Li, T.; Witzenbichler, B.; Schattenman, G.; Isner, J.M. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997, 275, 964–967. [CrossRef]

40. Werner, N.; Priller, J.; Laufs, U.; Endres, M.; Bohn, M.; Dirnagl, U.; Nickenig, G. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: Effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. *Arterioscler. Thromb. Vasc. Biol.* 2002, 22, 1567–1572. [CrossRef]

41. Werner, N.; Junk, S.; Laufs, U.; Link, A.; Walenta, K.; Bohn, M.; Nickenig, G. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. *Circ. Res.* 2003, 93, e17–e24. [CrossRef] [PubMed]

42. Stellos, K.; Langer, H.; Daub, K.; Schöenberger, T.; Gauss, A.; Geisler, T.; Bigalke, B.; Mueller, I.; Schumm, M.; Schaefier, I.; et al. Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells. *Circulation* 2008, 117, 206–215. [CrossRef] [PubMed]

43. Langer, H.F.; May, A.E.; Vestweber, D.; De Boer, H.C.; Hatzopoulos, A.K.; Gawaz, M. Platelet-induced differentiation of endothelial progenitor cells. *Semin. Thromb. Hemost.* 2007, 33, 136–143. [CrossRef] [PubMed]
44. Hagensen, M.K.; Raarup, M.K.; Mortensen, M.B.; Thim, T.; Nyengaard, J.R.; Falk, E.; Bentzon, J.F. Circulating endothelial progenitor cells do not contribute to regeneration of endothelium after murine arterial injury. Cardiovasc. Res. 2012, 93, 223–231. [CrossRef]

45. Tsuzuki, M. Bone marrow-derived cells are not involved in reendothelialized endothelium as endothelial cells after simple endothelial denudation in mice. Basic Res. Cardiol. 2009, 104, 601–611. [CrossRef]

46. Tanaka, K.; Sata, M.; Hirata, Y.; Nagai, R. Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ. Res. 2003, 93, 783–790. [CrossRef]

47. Tura, O.; Skinner, E.M.; Barclay, G.R.; Samuel, K.; Gallagher, R.C.; Brittan, M.; Hadoke, P.W.; Newby, D.E.; Turner, M.L.; Mills, N.L. Late outgrowth endothelial cells resemble mature endothelial cells and are not derived from bone marrow. Stem Cells 2013, 31, 338–348. [CrossRef]

48. Mitchell, A.; Fujisawa, T.; Newby, D.; Mills, N.; Cruden, N.L. Vascular injury and repair: A potential target for cell therapies. Future Cardiol. 2015, 11, 45–60. [CrossRef]

49. Tigges, U.; Komatsu, M.; Stallcup, W.B. Adventitial pericyte progenitor/mesenchymal stem cells participate in the restenotic response to arterial injury. J. Vasc. Res. 2013, 50, 134–144. [CrossRef]

50. Masuda, H.; Ashara, T. Clonogenic assay of endothelial progenitor cells. Trends Cardiovasc. Med. 2013, 23, 99–103. [CrossRef]

51. Hill, J.M.; Zalos, G.; Halcox, J.P.; Schenke, W.H.; Waclawiw, M.A.; Quyyumi, A.A.; Finkel, T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 2003, 348, 593–600. [CrossRef] [PubMed]

52. Bonello, L.; Basire, A.; Sabatier, F.; Paganelli, F.; Dignat-George, F. Endothelial injury induced by coronary angioplasty triggers mobilization of endothelial progenitor cells in patients with stable coronary artery disease. J. Thromb. Haemost. 2006, 4, 979–981. [CrossRef] [PubMed]

53. Peichev, M.; Naiyer, A.J.; Pereira, D.; Zhu, Z.; Lane, W.J.; Williams, M.; Oz, M.C.; Hicklin, D.J.; Witte, L.; Moore, M.A.; et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000, 95, 952–956. [CrossRef] [PubMed]

54. Gurevich, D.B.; David, D.T.; Sundararaman, A.; Patel, J. Endothelial heterogeneity in development and wound healing. Cells 2021, 10, 2338. [CrossRef] [PubMed]

55. Chen, Q.; Yang, M.; Wu, H.; Zhou, J.; Wang, W.; Zhang, H.; Zhao, L.; Zhu, J.; Zhou, B.; Xu, Q.; et al. Genetic lineage tracing analysis of c-kit(+) stem/progenitor cells revealed a contribution to vascular injury-induced neointimal lesions. J. Mol. Cell. Cardiol. 2018, 121, 277–286. [CrossRef]

56. Mause, S.F.; Ritzel, E.; Deck, A.; Vogt, F.; Liehn, E.A. Endothelial progenitor cells modulate the phenotype of smooth muscle cells and increase their neointimal accumulation following vascular injury. Thromb. Haemost. 2022, 122, 456–469. [CrossRef]

57. Bitterli, L.; Afan, S.; Buhler, S.; DiSanto, S.; Zwahlen, M.; Nagai, R. Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ. Res. 2003, 93, 783–790. [CrossRef]

58. Kou, F.; Zhu, C.; Wan, H.; Xue, F.; Wang, J.; Xiang, L.; Li, J. Endothelial progenitor cells as the target for cardiovascular therapy: A potential target for cell therapies. Future Cardiol. 2015, 11, 45–60. [CrossRef]

59. Budzyn, M.; Gryszczynka, B.; Boruczkowski, M.; Kaczmarek, M.; Begier-Krasinska, B.; Osinska, A.; Bukowska, A.; Iskra, M.; Kasprzak, M.P. The potential role of circulating endothelial and endothelial progenitor cells in the prediction of left ventricular hypertrophy in hypertensive patients. Front. Physiol. 2019, 10, 1005. [CrossRef]

60. Szpera-Gozdziewicz, A.; Majcherek, M.; Boruczkowski, M.; Gozdziwicz, T.; Dworacik, G.; Wierchow, L.; Breborowicz, G.H. Circulating endothelial cells, circulating endothelial progenitor cells, and von Willebrand factor in pregnancies complicated by hypertensive disorders. Am. J. Reprod. Immunol. 2017, 77, e12625. [CrossRef]

61. Hammadah, M.; Al Mheid, I.; Wilmot, K.; Ramadan, R.; Abdelhadi, N.; Alkhoder, A.; Obideen, M.; Pimple, P.M.; Levantsevych, O.; Kelli, H.M.; et al. Telomere shortening, regenerative capacity, and cardiovascular outcomes. Circ. Res. 2017, 120, 1130–1138. [CrossRef] [PubMed]

62. Dai, R.; Zhuo, H.; Chen, Y.; Zhang, K.; Dong, Y.; Chen, C.; Wang, W. Mechanism of isosorbide dinitrate combined with exercise training rehabilitation to mobilize endothelial progenitor cells in patients with coronary heart disease. Bioengineered 2021, 122, 943–953. [CrossRef]

63. Di Stolfo, G.; Mastroianno, S.; Ruggieri, M.; Fontana, A.; Marinucci, R.; Copetti, M.; Minervini, M.M.; Savino, L.; Mastroianno, M.; Savino, M.; et al. Timing of clopidogrel loading dose on peripheral blood endothelial progenitor cells, SDF-1alpha and neointimal hyperplasia in carotid stenting. Clin. Hemorheol. Microcirc. 2019, 72, 23–38. [CrossRef] [PubMed]

64. Brugioni, C.; Quintavalle, C.; D’Alessio, F.; Donahue, M.; Roscigno, G.; De Micco, F.; Focaccia, A.; Visconti, G.; Del Vecchio, L.; Madonna, R.; et al. Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. Int. J. Cardiol. 2017, 244, 112–118. [CrossRef]

65. Fadini, G.P.; Albiero, M.; Vigili de Kreutzenberg, S.; Boscaro, E.; Cappellari, R.; Marascotti, M.; Poncina, N.; Agostini, C.; Avogaro, A. Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care 2013, 36, 943–949. [CrossRef] [PubMed]

66. Lee, L.C.; Chen, C.S.; Choong, P.F.; Low, A.; Tan, H.C.; Poh, K.K. Time-dependent dynamic mobilization of circulating progenitor cells during percutaneous coronary intervention in diabetics. Int. J. Cardiol. 2010, 142, 199–201. [CrossRef]
67. Inoue, T.; Sata, M.; Hikichi, Y.; Sohma, R.; Fukuda, D.; Uchida, T.; Shimizu, M.; Komoda, H.; Node, K. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation: Impact on restenosis. *Circulation* **2007**, *115*, 553–561. [CrossRef]

68. Pelliccia, F.; Cianfrocca, C.; Rosano, G.; Mercuro, G.; Speciale, G.; Pasceri, V. Role of endothelial progenitor cells in restenosis and progression of coronary atherosclerosis after percutaneous coronary intervention: A prospective study. *JACC Cardiovasc. Interv.* **2010**, *3*, 78–86. [CrossRef]

69. Sakuma, M.; Nishino, S.; Nasuno, T.; Kageyama, M.; Tokura, M.; Sohma, R.; Inoue, K.I.; Kanaya, T.; Obi, S.; Toyoda, S.; et al. Mobilization of progenitor cells and vessel healing after implantation of SYNERGY in acute coronary syndrome. *Sci. Rep.* **2021**, *11*, 17315. [CrossRef]

70. Schober, A.; Hoffmann, R.; Opree, N.; Knarren, S.; Iofina, E.; Hutschenreuter, G.; Hanrath, P.; Weber, C. Peripheral CD34+ cells and the risk of in-stent restenosis in patients with coronary heart disease. *Am. J. Cardiol.* **2005**, *96*, 1116–1122. [CrossRef]

71. Haine, S.E.; Van Craenenbroeck, E.M.; Hoymans, V.Y.; Miljoen, H.P.; Vandendriessche, T.R.; Claeyys, M.J.; Frederix, G.; Conraads, V.M.; Bosmans, J.M.; Vrints, C.J. Levels of circulating CD34+ /KDR+ cells do not predict coronary in-stent restenosis. *Can. J. Cardiol.* **2014**, *30*, 102–108. [CrossRef] [PubMed]

72. Sakuma, M.; Nasuno, T.; Abe, S.; Obi, S.; Toyoda, S.; Taguchi, I.; Sohma, R.; Inoue, K.I.; Nishino, S.; Node, K.; et al. Mobilization of progenitor cells and assessment of vessel healing after second generation drug-eluting stenting by optical coherence tomography. *Int. J. Cardiol. Heart Vasc.* **2018**, *18*, 17–24. [CrossRef] [PubMed]

73. Montenegro, F.S.; Correia, M.; Muccillo, F.; Souza, E.S.G.; De Lorenzo, A. Associations between endothelial progenitor cells, clinical characteristics and coronary restenosis in patients undergoing percutaneous coronary artery intervention. *BMC Res. Notes* **2018**, *11*, 278. [CrossRef] [PubMed]

74. Pelliccia, F.; Pasceri, V.; Zimarino, M.; De Luca, G.; De Caterina, R.; Mehran, R.; Dangas, G. Endothelial progenitor cells in coronary atherosclerosis and percutaneous coronary intervention: A systematic review and meta-analysis. In *Cardiovascular Rervascularization Medicine*; Elsevier: Amsterdam, The Netherlands, 2022. [CrossRef]

75. Yang, F.; Feng, S.C.; Pang, X.J.; Li, W.X.; Bi, Y.H.; Zhao, Q.; Zhang, S.X.; Wang, Y.; Feng, B. Combination coating of chitosan and anti-CD34 antibody applied on sirolimus-eluting stents can promote endothelialization while reducing neointimal formation. *BMCCardiovasc. Disord.* **2012**, *12*, 96. [CrossRef]

76. Aoki, J.; Serruys, P.W.; van Beusekom, H.; Ong, A.T.; McFadden, E.P.; Sianos, G.; van der Giessen, W.J.; Regar, E.; de Feyter, P.J.; Davis, H.R.; et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: The HEALING-FIM (Healthy endothelial accelerated lining inhibits neointimal growth-first in man) registry. *J. Am. Coll. Cardiol.* **2005**, *45*, 1574–1579. [CrossRef]

77. Wohrle, J.; Birkemeyer, R.; Markovic, S.; Nguyen, T.V.; Sinha, A.; Miljak, T.; Spiess, J.; Rottbauer, W.; Rittger, H. Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease. *Heart* **2011**, *97*, 1338–1342. [CrossRef]

78. Zarpak, R.; Sanchez, O.D.; Joner, M.; Guy, L.G.; Leclerc, G.; Virmani, R. A novel “pro-healing” approach: The COMBO dual therapy stent from a pathological view. *Minerva Cardioangiol.* **2015**, *63*, 31–43.

79. Kalkman, D.N.; Kerkmeijer, L.S.; Woudstra, P.; Menown, I.B.A.; Suryapranata, H.; den Heijer, P.; Iniguez, A.; van’t Hof, A.W.J.; Erglis, A.; Arkenbout, K.E.; et al. Three-year clinical outcomes after dual-therapy COMBO stent placement: Insights from the REMEDEE registry. *Catheter. Cardiovasc. Interv.* **2019**, *94*, 342–347. [CrossRef]

80. Haude, M.; Lee, S.W.L.; Worthley, S.G.; Silber, S.; Verheyne, S.; Rosli, M.A.; Botelho, R.; Sim, K.H.; Abizaid, A.; Mehran, R.; et al. The REMEDEE trial: 5-Year results on a novel combined sirolimus-eluting and endothelial progenitor cells capturing stent. *Catheter. Cardiovasc. Interv.* **2020**, *95*, 1076–1084. [CrossRef]

81. Blessing, R.; Ahoopai, M.; Geyer, M.; Brandt, M.; Zeiher, A.M.; Munzel, T.; Wenzel, P.; Gori, T.; Dimitriadis, Z. The bioengineered combo dual-therapy CD34 antibody-covered sirolimus-eluting coronary stent in patients with chronic total occlusion evaluated by clinical outcome and optical coherence tomography imaging analysis. *J. Clin. Med.* **2020**, *10*, 80. [CrossRef]

82. Jakobsen, L.; Christiansen, E.H.; Freeman, P.; Kahler, J.; Veien, K.; Maeng, M.; Raungaard, B.; Ellert, J.; Kristensen, S.D.; Christiansen, M.K.; et al. Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent. *Catheter. Cardiovasc. Interv.* **2022**, *99*, 1965–1975. [CrossRef] [PubMed]

83. Jakobsen, L.; Christiansen, E.H.; Freeman, P.; Kahler, J.; Veien, K.; Maeng, M.; Raungaard, B.; Ellert, J.; Villadsen, A.B.; Kristensen, S.D.; et al. Randomized clinical comparison of the dual-therapy CD34 antibody-covered sirolimus-eluting combo stent with the sirolimus-eluting orsiro stent in patients treated with percutaneous coronary intervention: The SORt OUT X trial. *Circulation* **2021**, *143*, 2155–2165. [CrossRef] [PubMed]

84. Ndunda, P.; Vindhyl, M.R.; Muutu, T.; Fanari, Z. Clinical outcomes of the dual-therapy CD34 antibody-covered sirolimus-eluting stent versus standard drug-eluting coronary stents: A meta-analysis. *Cardiovasc. Revasc. Med.* **2020**, *21*, 213–221. [CrossRef] [PubMed]

85. Diaz-Rodriguez, S.; Rasser, C.; Mesnier, J.; Chevallier, P.; Gallet, R.; Choqueux, C.; Even, G.; Sayah, N.; Chaubet, F.; Nicoletti, A.; et al. Coronary stent CD31-mimetic coating favours endothelialization and reduces local inflammation and neointimal development in vivo. *Eur. Heart J.* **2021**, *42*, 1760–1769. [CrossRef]
86. Sarelo, P.; Duda, M.; Gasior-Głogowska, M.; Wysokinska, E.; Kalas, W.; Podbielska, H.; Wawrzynska, M.; Kopaczynska, M. Antibody CD133 biofunctionalization of ammonium acryloyldimethyltaurate and vinylpyrollidone co-polymer-based coating of the vascular implants. Materials 2020, 13, 5604. [CrossRef]

87. Wawrzynska, M.; Duda, M.; Wysokinska, E.; Strzadala, L.; Bialy, D.; Ulatowska-Jarza, A.; Kalas, W.; Kraszewski, S.; Paslawski, R.; Biernat, P.; et al. Functionalized CD133 antibody coated stent surface simultaneously promotes EPCs adhesion and inhibits smooth muscle cell proliferation-A novel approach to prevent in-stent restenosis. Colloids Surf. B Biointerfaces 2019, 174, 587–597. [CrossRef]

88. Sedaghat, A.; Sinning, J.M.; Paul, K.; Kirfel, G.; Nickenig, G.; Werner, N. First in vitro and in vivo results of an anti-human CD133-antibody coated coronary stent in the porcine model. Clin. Res. Cardiol. 2013, 102, 413–425. [CrossRef]

89. Park, K.S.; Kang, S.N.; Kim, D.H.; Kim, H.B.; Im, K.S.; Park, W.; Hong, Y.J.; Han, D.K.; Joung, Y.K. Late endothelial progenitor cell-capture stents with CD146 antibody and nanostructure reduce in-stent restenosis and thrombosis. Acta Biomater. 2020, 111, 91–101. [CrossRef]

90. Schulz, C.; Hecht, J.; Kruger-Genge, A.; Kratz, K.; Jung, F.; Lendlein, A. Generating aptamers interacting with polymeric surfaces for biofunctionalization. Macromol. Biosci. 2016, 16, 1776–1791. [CrossRef]

91. Tsukada, J.; Mela, P.; Jinzaki, M.; Tsukada, H.; Schmitz-Rode, T.; Vogt, F. Development of in vitro endothelialised stents—Review. Stem Cell Res. Rep. 2022, 18, 179–197. [CrossRef]

92. Wang, W.; Zhang, Y.; Hui, H.; Tong, W.; Wei, Z.; Li, Z.; Zhang, S.; Yang, X.; Tian, J.; Chen, Y. The effect of endothelial progenitor cell transplantation on neointimal hyperplasia and reendothelialisation after balloon catheter injury in rat carotid arteries. Stem Cell Res. Ther. 2021, 12, 99. [CrossRef] [PubMed]

93. Mause, S.F.; Ritzel, E.; Deck, A.; Vogt, F.; Liehn, E.A. Engagement of the CXCL12-CXCR4 axis in the interaction of endothelial progenitor cell and smooth muscle cell to promote phenotype control and guard vascular homeostasis. Int. J. Mol. Sci. 2022, 23, 867. [CrossRef] [PubMed]

94. Liu, N.M.; Stu, K.L.; Youn, J.Y.; Cai, H. Attenuation of neointimal formation with netrin-1 and netrin-1 preconditioned endothelial progenitor cells. J. Mol. Med. 2017, 95, 335–348. [CrossRef] [PubMed]

95. Huang, Y.H.; Xu, Q.; Shen, T.; Li, J.K.; Sheng, J.Y.; Shi, H.J. Prevention of in-stent restenosis with endothelial progenitor cell (EPC) capture stent placement combined with regional EPC transplantation: An atherosclerotic rabbit model. Cardiol. J. 2019, 26, 283–291. [CrossRef]

96. Birkeland, K.; Khandwalla, R.M.; Kedan, I.; Shufelt, C.L.; Mehta, P.K.; Minissian, M.B.; Wei, J.; Handberg, E.M.; Thomson, L.E.; Berman, D.S.; et al. Daily activity measured with wearable technology as a novel measurement of treatment effect in patients with coronary microvascular dysfunction: Substudy of a randomized controlled crossover trial. JMIR Res. Protoc. 2017, 6, e255. [CrossRef]

97. Gyongyosi, M.; Wojakowski, W.; Lemarchand, P.; Lunde, K.; Tendera, M.; Bartunek, J.; Marban, E.; Assmus, B.; Henry, T.D.; Traverse, J.H.; et al. Meta-analysis of cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ. Res. 2015, 116, 1346–1360. [CrossRef]

98. Xu, J.Y.; Liu, D.; Zhong, Y.; Huang, R.C. Effects of timing on intracoronary autologous bone marrow-derived cell transplantation in acute myocardial infarction: A meta-analysis of randomized controlled trials. Stem Cell Res. Ther. 2017, 8, 231. [CrossRef]

99. Schachinger, V.; Erbs, S.; Elsasser, A.; Haberbosch, W.; Hambrecht, R.; Holschermann, H.; Yu, J.; Corti, R.; Mathey, D.G.; Hamm, C.W.; et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med. 2006, 355, 1210–1221. [CrossRef]

100. Wollert, K.C.; Meyer, G.P.; Lotz, J.; Ringes-Lichtenberg, S.; Lippolt, P.; Breidenbach, C.; Fichtner, S.; Korte, T.; Hornig, B.; Messinger, D.; et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: The BOOST randomised controlled clinical trial. Lancet 2004, 364, 141–148. [CrossRef]

101. Lunde, K.; Solheim, S.; Aakhus, S.; Arnesen, H.; Abdelnoor, M.; Egeland, T.; Endresen, K.; Ilebekk, A.; Mangschau, A.; Fjeld, J.C.; et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med. 2006, 355, 1199–1209. [CrossRef]

102. Tendera, M.; Wojakowski, W.; Ruzyillo, W.; Chojnowska, L.; Kepka, C.; Tracz, W.; Musialek, P.; Piwowarska, W.; Nessler, J.; Buszman, P.; et al. Functionalized bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: Results of randomized, multicentre myocardial regeneration by intracoronary injection of a selected population of stem cells in acute myocardial infarction (REGENT) trial. Eur. Heart J. 2009, 30, 1313–1327. [CrossRef] [PubMed]

103. Roncalli, J.; Mouquet, F.; Piot, C.; Trochu, J.N.; Le Corvoisier, P.; Neuder, Y.; Le Tournieu, T.; Agostini, D.; Gaxotte, V.; Sportouch, C.; et al. Intracoronary autologous mononucleated bone marrow infuse for acute myocardial infarction: Results of the randomized multicenter BONAMI trial. Eur. Heart J. 2011, 32, 1748–1757. [CrossRef] [PubMed]

104. Traverse, J.H.; Henry, T.D.; Ellis, S.G.; Pepine, C.J.; Willerson, J.T.; Zhao, D.X.; Forder, J.R.; Byrne, B.J.; Hatzopoulos, A.K.; Penn, M.S.; et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: The LateTIME randomized trial. JAMA 2011, 306, 2110–2119. [CrossRef] [PubMed]
105. Makkar, R.R.; Smith, R.R.; Cheng, K.; Malliaras, K.; Thomson, L.E.; Berman, D.; Czer, L.S.; Marban, L.; Mendizabal, A.; Johnston, P.V.; et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial. *Lancet* 2012, 379, 895–904. [CrossRef]

106. Traverse, J.H.; Henry, T.D.; Pepine, C.J.; Willerson, J.T.; Zhao, D.X.; Ellis, S.G.; Forder, J.R.; Anderson, R.D.; Hatzopoulos, A.K.; Penn, M.S.; et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: The TIME randomized trial. *JAMA* 2012, 308, 2380–2389. [CrossRef]

107. Wohrle, J.; von Scheidt, F.; Schauwecker, P.; Wiesneth, M.; Markovic, S.; Schrezenmeier, H.; Hombach, V.; Rottbauer, W.; Bernhardt, P. Impact of cell number and microvascular obstruction in patients with bone-marrow derived cell therapy: Final results from the randomized, double-blind, placebo controlled intracoronary Stem Cell therapy in patients with Acute Myocardial Infarction (SCAMI) trial. *Clin. Res. Cardiol.* 2013, 102, 765–770. [CrossRef]

108. Surder, D.; Manka, R.; Lo Cicero, V.; Mocetti, T.; Rufibach, K.; Soncin, S.; Turchetto, L.; Radrizzani, M.; Astori, G.; Schwitter, J.; et al. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: Effects on global left ventricular function. *Circulation* 2013, 127, 1968–1979. [CrossRef]

109. Gastl, M.; Surder, D.; Corti, R.; Faruque Osmany, D.M.M.; Gotschy, A.; von Spizcak, J.; Sokolska, J.; Metzen, D.; Alkadhi, H.; Ruschitzka, F.; et al. Effect of intracoronary bone marrow-derived mononuclear cell injection early and late after myocardial infarction on CMR-derived myocardial strain. *Int. J. Cardiol.* 2020, 310, 108–115. [CrossRef]

110. Peregud-Pogorzelska, M.; Przybycien, K.; Baumert, B.; Kotowski, M.; Pius-Sadowska, E.; Safranow, K.; Peregud-Pogorzelski, J.; Kornczewicz-Jach, Z.; Paczkowska, E.; Machalinski, B. The effect of intracoronary infusion of autologous bone marrow-derived lineage-negative stem/progenitor cells on remodeling of post-infarcted heart in patient with acute myocardial infarction. *Int. J. Med. Sci.* 2020, 17, 985–994. [CrossRef]

111. Nicolau, J.C.; Furtado, R.H.M.; Silva, S.A.; Rochitte, C.E.; Rassi, A., Jr.; Moraes, J., Jr.; Quintella, E.; Costantini, C.R.; Korman, A.P.M.; Mattos, M.A.; et al. Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial. *Clin. Cardiol.* 2018, 41, 392–399. [CrossRef]